Eli Lilly & Company Chairman and CEO Dave Ricks sheds light on growth and success, the increase in weight loss drug ...

Eli Lilly CEO David Ricks, also an Adobe director, paid $1 million on Jan. 28 for 2,250 shares of the software company.

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

In total, 234 investments creating 13,500 new jobs over the next five years, 59% of which were in regional locations ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly ( LLY 0.69%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the ...

Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the second ...

"2024 was a highly successful year for Lilly," said Eli Lilly CEO David Ricks in a statement. In addition to success with its weight-loss drugs, Ricks cited "major data readouts for tirzepatide in ...

“It’s early days on a very, very large opportunity. There’s turbulence. I’ll own that,” Eli Lilly CEO David Ricks told investors during a call on Thursday when asked if the company is ...

Weight loss drugs are huge these days, and Eli Lilly (LLY ... working on treatments for Alzheimer’s disease as well, and Lilly CEO David Ricks brought out some news on those advances as well ...

Eli Lilly (NYSE: LLY) stock inched 2.5% higher through ... were up 102% for the year (just like for the quarter) at $11.71. CEO David Ricks characterized Lilly's 2024 performance as "highly ...